U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C2F6
Molecular Weight 138.0118
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEXAFLUOROETHANE

SMILES

FC(F)(F)C(F)(F)F

InChI

InChIKey=WMIYKQLTONQJES-UHFFFAOYSA-N
InChI=1S/C2F6/c3-1(4,5)2(6,7)8

HIDE SMILES / InChI

Molecular Formula C2F6
Molecular Weight 138.0118
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

PubMed

PubMed

TitleDatePubMed
Macular hole surgery and cataract extraction: combined vs consecutive surgery.
2010-09
Temperature and pressure dependence of the reaction 2CF3 (+ M) <==> C2F6 (+ M).
2010-04-15
Intraocular gas treatment for myopic foveoschisis.
2009-12-08
Management of bilateral acute hydrops secondary to keratoglobus with perfluoroethane (C2F6) pneumodescemetopexy.
2009-12
Mie potentials for phase equilibria calculations: application to alkanes and perfluoroalkanes.
2009-11-05
Comparison of gas-solid chromatography and MM2 force field molecular binding energies for greenhouse gases on a carbonaceous surface.
2009-10-01
Retinal detachment after primary pneumatic retinopexy.
2009-09-05
Modeling kinetics of subcellular disposition of chemicals.
2009-05
Influence of postoperative lens status on intraocular pressure in proliferative vitreoretinopathy.
2009-05
23-gauge sutureless vitrectomy and 20-gauge vitrectomy: a case series comparison.
2009-05
Interactions of fluorinated gases with ionic liquids: solubility of CF4, C2F6, and C3F8 in trihexyltetradecylphosphonium bis(trifluoromethylsulfonyl)amide.
2008-10-02
Comparison of face-down and seated position after idiopathic macular hole surgery: a randomized clinical trial.
2008-07
Delineation of the vitreous and posterior hyaloid using bromophenol blue.
2008-02
[Long-lasting expanding gases for the treatment of vitreo-retinal diseases].
2008-01
To posture or not to posture after macular hole surgery.
2008-01
A 40 degrees gaze down position for pneumatic displacement of submacular hemorrhage: clinical application and results.
2008-01
Combined phacovitrectomy for macular hole: long-term results.
2007-12-07
Outcomes of macular hole surgery in patients treated intraoperatively for retinal breaks and/or lattice degeneration.
2007-11-30
[Retinal detachment caused by ocular perforation during periocular anesthesia: three case reports].
2007-06
Atmospheric trends and radiative forcings of CF4 and C2F6 inferred from firn air.
2007-04-01
Five-year follow-up of macular hole surgery with peeling of the internal limiting membrane: update of a prospective study.
2006-07-11
Evaluation of macular changes before and after successful retinal detachment surgery using stratus-optical coherence tomography.
2006-07
The presence of an operculum verified by optical coherence tomography and other prognostic factors in macular hole surgery.
2006-06
Subsecond fluorine-19 MRI of the lung.
2006-04
Influence of relaxing retinotomy on surgical outcomes in proliferative vitreoretinopathy.
2005-10
Molecular dynamics simulations of C2F6 effects on gramicidin A: implications of the mechanisms of general anesthesia.
2005-06
[Experimental induction of posterior vitreous detachment in rabbits with hyaluronidase and perfluoroethane (C2F6)].
2004-07
Long-term follow-up after macular hole surgery with internal limiting membrane peeling.
2002-11
Effects of the nonimmobilizer hexafluroethane on the model membrane dimyristoylphosphatidylcholine.
2002-10
Macular changes after peeling of the internal limiting membrane in macular hole surgery.
2001-09
Development of perfluorocarbon (PFC) primary standards for monitoring of emissions from aluminum production.
2001-08
Adjuvant methods in macular hole surgery: intraoperative plasma-thrombin mixture and postoperative fluid-gas exchange.
2001-05-24
Senile schisis detachment with posterior outer layer breaks.
2001
Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration.
2001
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:28:31 GMT 2025
Edited
by admin
on Mon Mar 31 21:28:31 GMT 2025
Record UNII
7VL5Z0IY3A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HEXAFLUOROETHANE
Systematic Name English
PERFLUOROETHANE
Preferred Name English
Code System Code Type Description
WIKIPEDIA
HEXAFLUOROETHANE
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
FDA UNII
7VL5Z0IY3A
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
HSDB
7870
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
CHEBI
32905
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
PUBCHEM
6431
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
CAS
76-16-4
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
EPA CompTox
DTXSID2041915
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY
ECHA (EC/EINECS)
200-939-8
Created by admin on Mon Mar 31 21:28:31 GMT 2025 , Edited by admin on Mon Mar 31 21:28:31 GMT 2025
PRIMARY